ONCO
Onconetix, Inc.NASDAQHealthcareAs of 2026-04-07
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.32
P/S
6.43
EV/EBITDA
-0.00
DCF Value
$1.40
FCF Yield
-184.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.6%
Operating Margin
-2190.0%
Net Margin
-1721.0%
ROE
-189.8%
ROA
-56.3%
ROIC
-112.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $303.6K | $5.7M | $1.04 |
| FY 2025 | $815.4K | $-14.0M | $-4.73 |
| Q3 2025 | $303.7K | $-8.8M | $-1.79 |
| Q2 2025 | $106.5K | $-2.4M | $-1.36 |
Analyst Ratings
View AllConsensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
3.63
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.